[Combined radiomodification in the treatment of patients with disseminated laryngeal cancer].
The paper is devoted to comparative estimation of radiation and combined therapy of laryngeal cancer patients using combined radiomodification including local hyperthermia, total hyperthermia, chemotherapy and a method of dynamic dose fractionation. Complete and significant tumor regression at a dose of 32 Gy was noted in the study group (77 patients) and in the control group (64%). Radiotherapy against a background of combined radiomodification tends to increase the 3-year survival up to 86% as compared to 66.7% in the control group.
V G
VG
Andreev
Iu S
IuS
Mardynskiĭ
B O
BO
Shaimbetov
O K
OK
Kurpeshev
V F
VF
Lopatin
K G
KG
Filippov
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001761:Bleomycin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002294:Carcinoma, Squamous Cell / Q000150:complications / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D003131:Combined Modality Therapy / Q000379:methods; D005947:Glucose / Q000008:administration & dosage; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods; D007822:Laryngeal Neoplasms / Q000150:complications / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009367:Neoplasm Staging; D011832:Radiation Injuries / Q000453:epidemiology; D011879:Radiotherapy Dosage; D012074:Remission Induction
D000970:Antineoplastic Agents; D001761:Bleomycin; C025703:bleomycetin; D005947:Glucose; D008727:Methotrexate
Kompleksnaia radiomodifikatsiia pri lechenii bol'nykh rasprostranennym rakom gortani.